Omalizumab Treatment in Patients with Severe Allergic Asthma
Introduction:Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthm...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2017-09-01
|
| Series: | İstanbul Medical Journal |
| Subjects: | |
| Online Access: |
http://imj.galenos.com.tr/archives/archive-detail/article-preview/omalizumab-treatment-in-patients-with-severe-aller/20487
|
| _version_ | 1828014946009481216 |
|---|---|
| author | Tuğba Songül Tat Aykut Çilli |
| author_facet | Tuğba Songül Tat Aykut Çilli |
| author_sort | Tuğba Songül Tat |
| collection | DOAJ |
| description | Introduction:Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.Methods:The efficacy and safety of omalizumab treatment was assessed by analyzing the medical records of the patients. While patients were on omalizumab treatment, they were clinically evaluated monthly. The level of control of asthma symptoms as determined in the Global Initiative for Asthma (GINA) guideline was used to evaluate the efficacy of treatment.Results:Fifty-four patients were included. All patients were sensitive to at least one perennial allergen and had uncontrolled allergic asthma despite providing standard treatments. The mean±standard deviation (SD) age, body weight, and IgE level were 53.6±13.9 years, 75.4±14.3 kg, and 294.7±227.5 IU/mL, respectively. The mean±SD omalizumab treatment duration was 34.8±20.2 (range,10-84) months. Patients did not experience major adverse reactions that were considered related to omalizumab treatment. Two patients had local adverse reactions, and one had myalgia that was considered to be drug-related. After omalizumab treatment, asthma symptoms were well controlled in 25 patients (46.3%), partly controlled in 23 patients (42.6%), and uncontrolled in 6 patients (11.1%).Conclusion:Our study showed that omalizumab treatment is well tolerated and effective for patients with uncontrolled allergic asthma. Keywords: |
| first_indexed | 2024-04-10T10:10:36Z |
| format | Article |
| id | doaj.art-e2850ae634d04383b7412c71c7ae8e24 |
| institution | Directory Open Access Journal |
| issn | 2619-9793 2148-094X |
| language | English |
| last_indexed | 2024-04-10T10:10:36Z |
| publishDate | 2017-09-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | İstanbul Medical Journal |
| spelling | doaj.art-e2850ae634d04383b7412c71c7ae8e242023-02-15T16:22:15ZengGalenos Yayineviİstanbul Medical Journal2619-97932148-094X2017-09-0118313513810.5152/imj.2017.9365313049054Omalizumab Treatment in Patients with Severe Allergic AsthmaTuğba Songül Tat0Aykut Çilli1 Akdeniz Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Antalya, Türkiye Akdeniz Üniversitesi Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Antalya, Türkiye Introduction:Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.Methods:The efficacy and safety of omalizumab treatment was assessed by analyzing the medical records of the patients. While patients were on omalizumab treatment, they were clinically evaluated monthly. The level of control of asthma symptoms as determined in the Global Initiative for Asthma (GINA) guideline was used to evaluate the efficacy of treatment.Results:Fifty-four patients were included. All patients were sensitive to at least one perennial allergen and had uncontrolled allergic asthma despite providing standard treatments. The mean±standard deviation (SD) age, body weight, and IgE level were 53.6±13.9 years, 75.4±14.3 kg, and 294.7±227.5 IU/mL, respectively. The mean±SD omalizumab treatment duration was 34.8±20.2 (range,10-84) months. Patients did not experience major adverse reactions that were considered related to omalizumab treatment. Two patients had local adverse reactions, and one had myalgia that was considered to be drug-related. After omalizumab treatment, asthma symptoms were well controlled in 25 patients (46.3%), partly controlled in 23 patients (42.6%), and uncontrolled in 6 patients (11.1%).Conclusion:Our study showed that omalizumab treatment is well tolerated and effective for patients with uncontrolled allergic asthma. Keywords: http://imj.galenos.com.tr/archives/archive-detail/article-preview/omalizumab-treatment-in-patients-with-severe-aller/20487 Asthmaomalizumabsevere allergic asthmauncontrolled allergic asthma |
| spellingShingle | Tuğba Songül Tat Aykut Çilli Omalizumab Treatment in Patients with Severe Allergic Asthma İstanbul Medical Journal Asthma omalizumab severe allergic asthma uncontrolled allergic asthma |
| title | Omalizumab Treatment in Patients with Severe Allergic Asthma |
| title_full | Omalizumab Treatment in Patients with Severe Allergic Asthma |
| title_fullStr | Omalizumab Treatment in Patients with Severe Allergic Asthma |
| title_full_unstemmed | Omalizumab Treatment in Patients with Severe Allergic Asthma |
| title_short | Omalizumab Treatment in Patients with Severe Allergic Asthma |
| title_sort | omalizumab treatment in patients with severe allergic asthma |
| topic | Asthma omalizumab severe allergic asthma uncontrolled allergic asthma |
| url |
http://imj.galenos.com.tr/archives/archive-detail/article-preview/omalizumab-treatment-in-patients-with-severe-aller/20487
|
| work_keys_str_mv | AT tugbasongultat omalizumabtreatmentinpatientswithsevereallergicasthma AT aykutcilli omalizumabtreatmentinpatientswithsevereallergicasthma |